# Safety, Tolerability and Pharmacokinetics Study of QLH11906 in Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations.

> **NCT05488821** · PHASE1 · UNKNOWN · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Advanced Solid Tumors Harboring MAPK Pathway Alterations

## Interventions

- **DRUG:** QLH11906

## Key facts

- **NCT ID:** NCT05488821
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-14
- **Primary completion:** 2024-07-01
- **Final completion:** 2025-07-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05488821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05488821, "Safety, Tolerability and Pharmacokinetics Study of QLH11906 in Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05488821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*